文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

体外细胞因子吸附治疗在心脏手术中的预防作用及脓毒症中的辅助治疗作用:疗效与安全性更新系统评价

Extracorporeal Cytokine Adsorption Therapy As a Preventive Measure in Cardiac Surgery and As a Therapeutic Add-On Treatment in Sepsis: An Updated Systematic Review of Comparative Efficacy and Safety.
PubMed 文献 · Crit Care Med · 2021-01-01
一句话结论系统评价显示,体外细胞因子吸附在心脏手术预防和脓毒症辅助治疗中疗效与安全性均未确立,证据质量极低且无定论。

本系统评价检索Medline、Embase、Cochrane Library及欧洲卫生技术评估网络规划与在研项目数据库,纳入随机对照试验及有同期对照的前瞻性研究,评估体外细胞因子吸附治疗在心脏手术患者中的预防作用及在脓毒症/脓毒症休克患者中的治疗作用。采用Cochrane偏倚风险工具评价单个研究质量,采用GRADE方法评价证据强度。结果显示,心脏手术预防性治疗中,死亡率(5项RCT,n=163)、ICU住院时间(5项RCT,n=163)、住院时间(3项RCT,n=101)及(严重)不良事件(4项RCT,n=148)均为极低质量无定论证据;脓毒症/脓毒症休克治疗中,60天随访死亡率(2项RCT,n=117)、器官功能(2项RCT,n=117)、ICU住院时间(1项RCT,n=20)及(严重)不良事件(2项RCT,n=117)亦均为极低质量无定论证据。作者结论认为,在联合标准治疗的情况下,体外细胞因子吸附治疗在上述适应症中的疗效与安全性未确立,并强烈建议考虑开展以患者相关终点评价的、有足够把握度的研究,而非将研究资金继续投入可能无法阐明其临床获益的研究。

要点

  • 心脏手术预防性体外细胞因子吸附:死亡率(5项RCT,n=163)、ICU住院时间(5项RCT,n=163)、住院时间(3项RCT,n=101)均为极低质量无定论证据。
  • 心脏手术预防性体外细胞因子吸附:(严重)不良事件(4项RCT,n=148)为极低质量无定论证据。
  • 脓毒症/脓毒症休克治疗性体外细胞因子吸附:60天随访死亡率(2项RCT,n=117)、器官功能(2项RCT,n=117)为极低质量无定论证据。
  • 脓毒症/脓毒症休克治疗性体外细胞因子吸附:ICU住院时间(1项RCT,n=20)及(严重)不良事件(2项RCT,n=117)为极低质量无定论证据。
  • 作者强烈建议考虑开展以患者相关终点评价的、有足够把握度的研究,而非将研究资金继续投入可能无法阐明临床获益的研究。

适用人群与场景

  • 接受心脏手术的患者(用于预防性治疗)。
  • 脓毒症/脓毒症休克患者(用于治疗性辅助治疗)。

研究设计与关键结果

  • 研究设计:系统评价;检索Medline、Embase、The Cochrane Library及欧洲卫生技术评估网络规划与在研项目数据库;纳入随机对照试验及有同期对照的前瞻性研究;采用Cochrane偏倚风险工具评价单个研究质量,采用GRADE方法评价证据强度。
  • 心脏手术预防性治疗:死亡率(5项RCT,n=163)、ICU住院时间(5项RCT,n=163)、住院时间(3项RCT,n=101)均为极低质量无定论证据。
  • 心脏手术预防性治疗:(严重)不良事件(4项RCT,n=148)为极低质量无定论证据。
  • 脓毒症/脓毒症休克治疗性治疗:60天随访死亡率(2项RCT,n=117)、器官功能(2项RCT,n=117)、ICU住院时间(1项RCT,n=20)均为极低质量无定论证据。
  • 脓毒症/脓毒症休克治疗性治疗:(严重)不良事件(2项RCT,n=117)为极低质量无定论证据。

证据类型、等级与局限

  • 证据类型:系统评价;采用GRADE方法评价证据强度,上述所有结局的证据质量均为极低质量,结论为无定论。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为,鉴于现有证据,体外细胞因子吸附治疗联合标准治疗在心脏手术预防和脓毒症/脓毒症休克治疗中的疗效与安全性未确立。
  • 作者强烈建议考虑开展以患者相关终点评价的、有足够把握度的研究,而非将研究资金继续投入可能无法阐明体外细胞因子吸附治疗临床获益的研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Evaluating whether there is a clinical benefit of using extracorporeal cytokine adsorption therapy in two indications.

DESIGN: Systematic review.

SETTING: Search on four databases, Medline, Embase, The Cochrane Library, and the European Network for Health Technology Assessment planned and ongoing projects database.

PATIENTS: Patients with sepsis/septic shock; patients undergoing cardiac surgery.

INTERVENTIONS: Cytokine adsorption.

MEASUREMENTS AND MAIN RESULTS: Randomized controlled trials and prospective studies with concurrent control were eligible for the evidence synthesis. The quality of the individual studies and the strength of the available evidence were assessed using the Cochrane risk of bias tool and the Grading of Recommendations, Assessment, Development, and Evaluation approach, respectively. For the preventive treatment of extracorporeal cytokine adsorption therapy in patients undergoing cardiac surgery, we found very low-quality inconclusive evidence for mortality (five randomized controlled trials, n = 163), length of stay in the ICU (five randomized controlled trials, n = 163), and length of hospitalization (three randomized controlled trials, n = 101). Very low-quality inconclusive evidence was found for (serious) adverse events (four randomized controlled trials, n = 148). For the therapeutic treatment of extracorporeal cytokine adsorption therapy in patients with sepsis/septic shock, we found very low-quality inconclusive evidence for mortality up to 60-day follow-up (two randomized controlled trials, n = 117), organ function (two randomized controlled trials, n = 117) and length of stay in the ICU (one randomized controlled trial, n = 20). Very low-quality inconclusive evidence was found for (serious) adverse events (two randomized controlled trials, n = 117).

CONCLUSIONS: Given the available evidence, the efficacy and safety of extracorporeal cytokine adsorption therapy in combination with standard care in the investigated indications was not established. We strongly recommend considering well-powered studies with patient-relevant endpoints instead of investing further research funds on studies that may not shed light on the clinical benefit of extracorporeal cytokine adsorption therapy.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Goetz G, Hawlik K, Wild C, et al. Extracorporeal Cytokine Adsorption Therapy As a Preventive Measure in Cardiac Surgery and As a Therapeutic Add-On Treatment in Sepsis: An Updated Systematic Review of Comparative Efficacy and Safety. Crit Care Med. 2021. PMID: 33935160. doi:10.1097/CCM.0000000000005023

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。